Newborn Screening for Hemoglobinopathies a

Clinical and Laboratory Standards Institute guideline NBS08—Newborn Screening for Hemoglobinopathies describes the newborn screening (NBS) processes for testing dried blood spot specimens to detect hemoglobinopathies and thalassemias not usually evident at birth. Hemoglobinopathies and thalassemias are clinically significant congenital red blood cell disorders caused by structural or other hemoglobin abnormalities, resulting in various clinical manifestations. Early detection is critical, because without treatment, these conditions lead to increased morbidity and mortality. This guideline discusses various NBS approaches, including equipment considerations, laboratory screening methodologies, short-term and long-term follow-up processes, and future screening possibilities. Clinical and Laboratory Standards Institute (CLSI). Newborn Screening for Hemoglobinopathies. 1st ed. CLSI guideline NBS08 (ISBN 978-1-68440-059-1 [Print]; ISBN 978-1-68440-060-7 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2019. The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org. If you or your organization is not a member and would like to become one, or to request a copy of the catalog, contact us at: Telephone: +1.610.688.0100; Fax: +1.610.688.0700; E-Mail: customerservice@clsi.org; Website: www.clsi.org. SA MP LE